A new view on development of a Staphylococcus aureus vaccine

When rationally designing a vaccine against a specific pathogen, several categories of microbiologic and immunologic data can offer insight. The identification of the protective antigen is of paramount importance. Another is the nature of the immune response to natural infection, which presumably is protective against recurrent infection caused by the same pathogen. A third category concerns the insight that is sometimes gained from understanding the nature of host defense immunologic defects that predispose to, or increase the severity of, the pathogen in question.

[1]  J. Farber,et al.  Th1-Th17 Cells Mediate Protective Adaptive Immunity against Staphylococcus aureus and Candida albicans Infection in Mice , 2009, PLoS pathogens.

[2]  A. Stringaro,et al.  Protection by Anti-β-Glucan Antibodies Is Associated with Restricted β-1,3 Glucan Binding Specificity and Inhibition of Fungal Growth and Adherence , 2009, PloS one.

[3]  B. Spellberg,et al.  Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. , 2009, FEMS immunology and medical microbiology.

[4]  C. Sasakawa,et al.  Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. , 2009, Immunity.

[5]  A. Husain,et al.  Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. , 2008, The Journal of infectious diseases.

[6]  S. Plotkin,et al.  Vaccines: correlates of vaccine-induced immunity. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  P. Lipke,et al.  The Antifungal Vaccine Derived from the Recombinant N Terminus of Als3p Protects Mice against the Bacterium Staphylococcus aureus , 2008, Infection and Immunity.

[8]  Roberta B Carey,et al.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.

[9]  B. Diep,et al.  Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Roberta B Carey,et al.  Methicillin-resistant S. aureus infections among patients in the emergency department. , 2006, The New England journal of medicine.

[11]  J. Takala,et al.  A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  R. Rappuoli,et al.  A novel glyco-conjugate vaccine against fungal pathogens , 2005, The Journal of experimental medicine.

[13]  R. Lynfield,et al.  Methicillin-resistant Staphylococcus aureus disease in three communities. , 2005, The New England journal of medicine.

[14]  A. Fattom,et al.  Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. , 2004, Vaccine.

[15]  A. Fattom,et al.  Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. , 2004, American heart journal.

[16]  A. Fattom,et al.  Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. , 2004, Vaccine.

[17]  H. Davies,et al.  Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. , 2003, The Journal of infectious diseases.

[18]  S. Black,et al.  Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. , 2002, The New England journal of medicine.

[19]  A. Jensen,et al.  Risk factors for hospital-acquired Staphylococcus aureus bacteremia. , 1999, Archives of internal medicine.